Advertisement
Home Tags Diabetes: Type II

Tag: Diabetes: Type II

Type 2 Diabetes Remission Maintained After RYGB Despite Weight Regain

Overall rate of continued diabetes remission higher for those undergoing RYGB versus sleeve gastrectomy

Sodium-Glucose Cotransporter 2 Inhibitors Tied to Lower Kidney Stone Risk

Findings seen compared with glucagon-like peptide 1 receptor agonists or dipeptidyl peptidase 4 inhibitors

Exercise Intensity, Duration Can Affect CKD Risk in Obesity, Type 2 Diabetes

Inverse link seen for total MVPA, MVPA accumulated in bouts of ≥10 minutes with progression to CKD in overweight/obese adults with T2D

GLP1 Agonists Reduce Major Adverse Liver Outcomes in Chronic Liver Disease

For patients with chronic liver disease and type 2 diabetes, GLP1 agonist initiators associated with lower risk for major adverse liver outcomes

Risk for CKD, CVD Lower for Adults With Evidence of Type 2 Diabetes Remission

Significantly lower risks of chronic kidney disease, composite cardiovascular disease measure seen for those with any remission

Type 2 Diabetes Remission Likely With Weight Loss After Diagnosis

Increased likelihood of diabetes remission and reduced risk for returning to hyperglycemia seen with weight loss in year after diagnosis

Healthful Plant-Based Diet May Lower Risk for Type 2 Diabetes

Association with lower risk for T2DM partially mediated by lower BMI, lower waist circumference, and lower HbA1c, triglycerides

Risk for Suicidal Ideation Not Increased With Semaglutide

No increased risk for suicidal ideation seen with semaglutide versus non-GLP1R agonist antiobesity medications

Dapagliflozin Cuts Cardiovascular Events in Patients With Heart Failure, T2D

However, dapagliflozin does not reduce urinary albumin-to-creatinine ratio in these patients

Treatment Modification Common With Second-Line Antidiabetic Meds

Lowest adjusted risk of switching and highest intensification risk for patients prescribed sufonylureas